- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.03. | Hyloris Pharmaceuticals SA: Hyloris Reports Full Year Results for 2023 & Provides Business Outlook | 350 | GlobeNewswire (Europe) | Hyloris Reports Full Year Results for 2023 & Provides Business Outlook Total revenue and other income amounted to €4.4 millionStronger growth expected in 2024 of both sales and gross margin, mainly... ► Artikel lesen | |
| 14.03. | Hyloris Pharmaceuticals SA: Communication at the request of the FSMA on the transactions with Qliniq | 182 | GlobeNewswire (Europe) | Communication at the request of the FSMA on the transactions with Qliniq Revision of 2022 and half-year of 2023 (HY 2023) financial statements following a correction of a non-cash error in the... ► Artikel lesen | |
| 08.03. | Hyloris Pharmaceuticals SA: Hyloris to Report 2023 Full-Year Results on 14 March 2024 | 1 | GlobeNewswire (USA) | ||
| 27.02. | Hyloris Pharmaceuticals SA: Hyloris Announces Launch of Maxigesic IV in the U.S. and approval In Canada | 482 | GlobeNewswire (Europe) | Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada Maxigesic® IV, a Potent Non-opioid Painkiller, Marketed in the U.S. under the Tradename Combogesic® IVMaxigesic® IV approved... ► Artikel lesen | |
| 14.02. | Hyloris Pharmaceuticals SA: Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures | 136 | GlobeNewswire (Europe) | Innovative oral care solution aims to benefit patients taking blood thinning medications, who have an increased risk of prolonged bleeding during and after dental procedures Approximately 280 patients... ► Artikel lesen | |
| 30.01. | Hyloris Pharmaceuticals SA: Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) | 133 | GlobeNewswire (Europe) | Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms with the combination of Miconazole (2%) and... ► Artikel lesen | |
| 18.01. | Hyloris Pharmaceuticals SA: Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS) | 165 | GlobeNewswire (Europe) | Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS) Equal Partnership with AFT Pharmaceuticals for Development of a Drug Releasing Mucoadhesive Film for VLS (HY-091)Limited... ► Artikel lesen | |
| 16.01. | Hyloris Pharmaceuticals SA: Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML) | 138 | GlobeNewswire (Europe) | Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML) PTX-252 (previously referenced as a PlecoidAgent) is a novel molecular entity developed in... ► Artikel lesen | |
| 26.12.23 | Hyloris Pharmaceuticals SA: Hyloris Announces Positive Clinical Study Results for Valacyclovir Oral Suspension (HY-029) | 289 | GlobeNewswire (Europe) | Valacyclovir is an Antiviral Medication that is Commonly Used to Treat Infections Caused by Herpes Viruses Clinical Study Demonstrates Comparable Relative Bioavailability to Valaciclovir Tablets under... ► Artikel lesen | |
| 21.12.23 | Hyloris Pharmaceuticals SA: Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome | 174 | GlobeNewswire (Europe) | Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome Equal Partnership with AFT Pharmaceuticals for Development of a Novel Locally-Acting Product Candidate in Burning Mouth... ► Artikel lesen | |
| 04.12.23 | Hyloris Pharmaceuticals SA: Hyloris announces US FDA approval for Podofilox Gel | 171 | GlobeNewswire (Europe) | Hyloris announces US FDA approval for Podofilox Gel Product previously referenced as HY-016, targeting genital and perianal wartsUS Commercialization by partner Padagis to start in December 2023Second... ► Artikel lesen | |
| 24.10.23 | Hyloris Pharmaceuticals SA: Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in Canada | 745 | GlobeNewswire (Europe) | Territorial expansion for a product candidate previously exclusively targeting the U.S.Kye Pharmaceuticals to register and commercialize in Canada Liège, Belgium - 24 October 2023 - 7AM CET - Non-regulated... ► Artikel lesen | |
| 18.10.23 | Hyloris Pharmaceuticals SA: Hyloris announces U.S. FDA Approval of Maxigesic IV | 241 | GlobeNewswire (Europe) | Maxigesic® IV, a potent non-opioid painkiller, to be marketed in the U.S. under the tradename Combogesic® IVFirst U.S. sales expected in early 2024, triggering a milestone payment of USD 2,1 million... ► Artikel lesen | |
| 06.09.23 | Hyloris Pharmaceuticals SA: Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business Outlook | 335 | GlobeNewswire (Europe) | Total revenue and other income nearly doubled (€2,4 million, +95%)R&D progress across the board, including initiation of the 4-arm Phase 2 clinical trial for AlenuraTM, targeting IC/BPS, a condition... ► Artikel lesen | |
| 13.06.23 | Hyloris Pharmaceuticals SA: Hyloris shareholders approve all resolutions at the Annual General Meeting | 233 | GlobeNewswire (Europe) | 56,22% of shares represented physically, virtually or by proxy voteAll documents related to the 2023 AGM are available on the Hyloris website Regulated Information - Inside Information - Liège, Belgium... ► Artikel lesen | |
| 28.04.23 | Hyloris Pharmaceuticals SA: Hyloris releases Annual Report 2022, including ESG objectives | 479 | GlobeNewswire (Europe) | Publication of the annual report for financial year 2022Environmental, Social and Governance objectives disclosed in initial report on ESGAnnual Shareholders Meeting on Tuesday, 13th of June 2023 Liège... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 114,98 | -2,39 % | Erwerb der Cardior Pharmaceuticals GmbH durch die Novo Nordisk A/S freigegeben | Das Bundeskartellamt hat die geplante Übernahme sämtlicher Anteile der Cardior Pharmaceuticals GmbH mit Sitz in Hannover durch die dänische Novo Nordisk A/S freigegeben. Cardior ist ein Biotech-Unternehmen... ► Artikel lesen | |
| ELI LILLY | 678,00 | -0,89 % | Eli Lilly, SuperMicro und mehr: Die 10 überbewertesten Tech-Aktien im S&P 500 | © Foto: Peter Morgan - picture alliance/AP Images Angesichts der aktuellen Marktschwankungen warnen Experten vor überbewerteten Aktien - darunter namhafte S&P-500-Unternehmen.Die wichtigsten US-Indizes... ► Artikel lesen | |
| OPKO HEALTH | 1,159 | +1,22 % | OPKO Health, Inc.: AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV | • Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans• Candidate showed similar half-life to standard monoclonal antibodies... ► Artikel lesen | |
| INVENTIVA | 2,980 | +0,68 % | INVENTIVA: Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F | Daix (France), Long Island City (New York, United States), April 3, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| FINANCIERE DE TUBIZE | 90,30 | -1,53 % | Financière de Tubize SA: Convening of the ordinary general meeting of shareholders of April 26, 2024 | Convening of the Ordinary General Meeting of shareholders of 26 april 2024
The shareholders are invited to attend the ordinary general meeting, which will take place on Friday 26th of April 2024... ► Artikel lesen | |
| BAYER | 27,275 | +1,13 % | DAX-Check LIVE: Bayer, Covestro, Munich Re, Sartorius Vz., Siemens, Siemens Energy im Fokus | Der DAX startete gestern einen erneuten Erholungsversuch. Gegen Mittag eroberte er die 17.900 Punkte-Marke zurück. Am Ende des Tages blieb dann aber nicht viel von den Zugewinnen übrig. Er ging lediglich... ► Artikel lesen | |
| MERCK KGAA | 149,95 | -1,58 % | Merck: Kursziel 200 Euro bestätigt - Ist das die Einstiegschance? | Merck-Aktien ISIN: DE0006599905 gehören in der vergangenen Handelswoche mit knapp 5 Prozent minus zu den größten Verlierern im DAX. Nach einem Jahreshoch bei 164,85 Euro geht es steil nach unten und... ► Artikel lesen | |
| ASTRAZENECA | 139,90 | +5,51 % | Verhaltene Kauflaune bei Aktie von AstraZeneca plc (64,2491 €) | Wenig Kursbewegung aktuell bei dem Anteilsschein von AstraZeneca plc . Die Aktie notiert derzeit bei 68,39 US-Dollar. Kaum auffällig ist zur Stunde an der Börse der Kurs von AstraZeneca plc . Das Papier... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,900 | 0,00 % | OPI, RVNC and AQST are among after hour movers | ||
| SANOFI | 90,82 | +3,89 % | Sanofi: Das steckt hinter dem Kursfeuerwerk | Die Aktie von Sanofi hat heute Vormittag eine deutliche Aufwärtsbewegung erfahren, ein Trend, der eine Wende nach einer Phase der Unsicherheit signalisiert. Grund dafür sind die jüngst veröffentlichten... ► Artikel lesen | |
| SUNSHINE BIOPHARMA | 0,930 | 0,00 % | Pre-market Movers: Zhongchao, Redwoods Acquisition Corp., Tritium DCFC, Nexalin Technology, Sunshine Biopharma | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.05 A.M. ET).In the Green Zhongchao Inc. (ZCMD) is up over 96% at $2.83.
Redwoods... ► Artikel lesen | |
| SCHOTT PHARMA | 38,980 | -0,31 % | SCHOTT Pharma-Aktie kann Vortagsniveau nicht halten (37,50 €) | Das Wertpapier von SCHOTT Pharma notiert am Donnerstag ein wenig leichter. Das Papier kostete zuletzt 37,50 Euro. An der Börse liegt das Wertpapier von SCHOTT Pharma gegenwärtig im Minus. Die Aktie... ► Artikel lesen | |
| OMNIAB | 4,560 | 0,00 % | OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program... ► Artikel lesen | |
| NEUROGENE | 30,230 | 0,00 % | Neurogene Inc. - 8-K, Current Report | ||
| CANOPY GROWTH | 8,390 | 0,00 % | Aurora Cannabis & Canopy Growth: Deshalb ziehen sie an | Die Aurora Cannabis-Aktie (WKN: A2P4EC) und die Aktie von Canopy Growth (WKN: A140WQA) haben am Donnerstag plötzlich einen massiven Kurssprung von über +20% vollführt. Das steckt hinter dem rasanten... ► Artikel lesen |
Das Unternehmen HYLORIS PHARMACEUTICALS SA kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,19 % bei einem Aktienkurs von 11,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
